GT Biopharma IncNASDAQ:GTBP
- LAST PRICE3.6500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.5300/ 15
- Ask / Lots3.9600/ 1
- Open / Previous Close0.0000 / 3.6500
- Day Range---
- 52 Week Range
- Volume372
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | GTBP |
|---|
Mar 26, 2024
*DJ GT Biopharma 4Q Loss $3M >GTBP, from 5:02PM ET on Tuesday Mar 26, 2024 by Dow Jones
5:02PM ET on Tuesday Mar 26, 2024 by Dow JonesGT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results, from 5:00PM ET on Tuesday Mar 26, 2024 by Dow Jones
5:00PM ET on Tuesday Mar 26, 2024 by Dow JonesGT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results, from 5:00PM ET on Tuesday Mar 26, 2024 by Dow Jones
5:00PM ET on Tuesday Mar 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
GT Biopharma Inc | 5.0M | -0.7x | --- |
Gold River Productions Inc | 5.3M | 0.0x | --- |
Processa Pharmaceuticals Inc | 4.6M | -0.2x | --- |
Hoth Therapeutics Inc | 5.8M | -0.5x | --- |
Eastgate Biotech Corp | 5.7M | -1.6x | --- |
AgriFORCE Growing Systems Ltd | 3.4M | 0.0x | --- |
Company Information
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. Its TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer (NK) cells. The Company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease such as for the treatment of patients infected by the human immunodeficiency virus (HIV). Its GTB-3550 is the first-generation TriKE product candidate which was a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15, all connected by small peptide linkers.
Contact Information
- Headquarters
- 8000 MARINA BLVD, SUITE 100BRISBANE, CA, United States 94005
- Phone
- 310-551-4020
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board, Interim Chief Executive Officer
- Michael Breen
- Independent Vice Chairman of the Board
- Bruce Wendel
- Chief Financial Officer, Company Secretary
- Manu Ohri
- Independent Director
- Charles Casamento
- Independent Director
- Rajesh Shrotriya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.61 |
EPS | $-5.57 |
Book Value | $5.41 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
